Oracle
ORCL
Salesforce
CRM
Microsoft
MSFT
Cisco
CSCO
Broadcom
AVGO
US Stock MarketDetailed Quotes
RPTX Repare Therapeutics
- 1.280
- -0.100-7.25%
Close Jan 8 16:00 ET
- 1.370
- +0.090+7.03%
Pre 06:08 ET
54.41MMarket Cap-0.64P/E (TTM)
1.385High1.250Low548.78KVolume1.360Open1.380Pre Close712.12KTurnover2.45%Turnover RatioLossP/E (Static)42.51MShares8.49052wk High0.31P/B28.69MFloat Cap1.20052wk Low--Dividend TTM22.41MShs Float46.440Historical High--Div YieldTTM9.78%Amplitude1.200Historical Low1.297Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Repare Therapeutics Stock Forum
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Realigning resources to extend runway to mid-2027
Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025
Exploring partnerships for continued development of Lunre+Camo and other assets
January 09, 2025 04:05 PM Eastern Standard Time
CAMBRIDGE, Mass. & MONTREAL--...
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial eva...
*************************************
REVERSE...
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday, 12th December at 4:20 pm
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics has announced a Cooperative Research and Development Agreement (CRADA) with the US National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) to advance camonsertib, their oral ATR inhibitor for cancer treatment. The drug has shown significant anti-tumor activity in preclinical and clinical studies, particularly ...
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results From the Phase 1 Mythic Clinical Trial
5 MINUTES AGO, 7:05 AM EDT
VIA BUSINESSWIRE
📊⚡️📊
No comment yet